Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| New York Genome Center | RCV001291663 | SCV001480242 | uncertain significance | Kabuki syndrome 1 | 2019-09-13 | criteria provided, single submitter | clinical testing | The c.14519G>A (p.Gly4840Glu) variant identified in the KMT2D gene substitutes a well conserved Glycine for Glutamic Acid at amino acid 4840/5538 (coding exon 47/54). This variant is found in a single individual in gnomAD (1 heterozygote, 0 homozygotes; allele frequency: 3.19e-5) and is absent from ExAC, suggesting it is not a common benign variant in the populations represented in these databases. In silico algorithms do not agree on the consequence of this variant, as it is predicted both Neutral (Provean;score:-1.02) and Damaging (SIFT; score:0.003) to the function of the canonical transcript. This variant is absent from ClinVar and to our current knowledge has not been identified in any affected individuals in the literature. Given the lack of compelling evidence for its pathogenicity, the c.14519 (p.Gly4840Glu) variant in the KMT2D gene is reported here as a Variant of Uncertain Significance. |
| Labcorp Genetics |
RCV005094350 | SCV005813725 | benign | Kabuki syndrome | 2024-09-01 | criteria provided, single submitter | clinical testing |